A major study has put two diabetes drugs head to head, and drawn some surprising conclusions. Avandia, a newer form of type 2 diabetes drug, was put alongside metformin and glyburide and thoroughly tested. Results indicated that Avandia provided better glucose control but posed a risk of greater side effects, not to mention a higher cost.
The study was conducted at the University of Washington . Glyburide was outperformed by both Avandia and Metformin, leading study author Steven Kahn to say: “People who use glyburide will have to think about changing drugs.”
The study was funded by the manufacturer of Avandia, GlaxoSmithKline, and investigated 4, 360 newly diagnosed diabetics . The flipside of the study, that proved the efficiency of Avandia, also revealed that 62 of the patients who took Avandia also developed a heart problem . When compared to the other drugs, 58 patients taking metformin and 41 taking glyburide developed similar heart problems .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…